title: Pingyangmycin with triamcinolone acetonide effective for treatment of lymphatic malformations in the oral and maxillofacial region.
abstract: OBJECTIVE
  The aim of this study was to evaluate the therapeutic effects of intralesion injection of pingyangmycin in combination with triamcinolone acetonide or pingyangmycin alone on lymphatic malformations in oral and maxillofacial regions.
  
  
  METHODS
  Twenty-nine cases with lymphatic malformations in the oral and maxillofacial region were divided into experimental and control groups. Thirteen patients in the experimental group underwent intralesion injections of pingyangmycin in combination with triamcinolone acetonide, and 16 patients of control group underwent intralesion injections of pingyangmycin alone. The effects of treatments were assessed by measuring lesion volume and facial deformity before and after treatment.
  
  
  RESULTS
  Two years after the treatment, the volumes of macrocystic and microcystic lesions were 3.7% ± 0.3 and 4.2% ± 0.4 of pre-treatment volume in the experimental group, respectively, whereas the volumes of macrocystic and microcystic lesions in control group were 15.4% ± 1.3 and 24.1% ± 3.1, respectively. Facial appearance was satisfactory in all subjects in the experimental group, whereas facial asymmetry remained in varying degree in control group.
  
  
  CONCLUSIONS
  Intralesion injection of pingyangmycin with triamcinolone acetonide was more effective than pingyangmycin alone for treatment of lymphatic malformations in oral and maxillofacial regions.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, 22 Zhongguancun Nandajie, Haidian District, Beijing 100081, China. luopeking@163.com
authors.forename: Quan-Feng
authors.initials: QF
authors.lastname: Luo
authors.forename: Ye-Hua
authors.initials: YH
authors.lastname: Gan
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004954:Esthetics; D005145:Face / Q000002:abnormalities*; D005146:Facial Asymmetry / Q000188:drug therapy / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015552:Injections, Intralesional; D044148:Lymphatic Abnormalities / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D017060:Patient Satisfaction; D010781:Photography; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D012597:Sclerosing Solutions; D001761:Bleomycin; C025703:bleomycetin; D014222:Triamcinolone Acetonide